World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA
Open Access
- 1 January 2012
- journal article
- Published by Taylor & Francis in mAbs
- Vol. 4 (1) , 4-13
Abstract
With more than 30 therapeutic monoclonal antibodies (mAbs) approved and annual global sales of the products at ~$50 billion in 2010, these products have proven to be successful in many ways. Nevertheless, there is room for improvement in performance, and substantial unmet medical needs remain. As a consequence, numerous organizations are devoting resources to engineering novel mAbs such as bispecific antibodies that have increased functionality compared with unmodified IgG molecules. The World Bispecific Antibody Summit, organized by Hanson Wade, drew over 100 participants to Boston to discuss engineering novel bispecific antibodies, generating lead candidates and clinical study and commercialization of the molecules. Approaches such as the trifunctional antibody (TRION), dual variable domain-Ig (Abbott), two-in-one (Genentech), dual affinity retargeting (MacroGenics), kappa-lambda body (NovImmune), bispecific T-cell engager (Micromet) and chemical generation (CovX/Pfizer) were discussed in detail. In add...Keywords
This publication has 35 references indexed in Scilit:
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesProceedings of the National Academy of Sciences, 2011
- Bispecific digoxigenin-binding antibodies for targeted payload deliveryProceedings of the National Academy of Sciences, 2011
- Chemical generation of bispecific antibodiesProceedings of the National Academy of Sciences, 2010
- Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffoldArthritis & Rheumatism, 2010
- Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell DepletionJournal of Molecular Biology, 2010
- Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering EffectsJournal of Biological Chemistry, 2010
- Mode of cytotoxic action of T cell-engaging BiTE antibody MT110Immunobiology, 2009
- Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding SiteScience, 2009
- B lymphocytes: how they develop and functionBlood, 2008
- ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerizationProtein Engineering, Design and Selection, 1996